Walter A Boiten1, Inger van Steenoven1,2, Mei-Fang Xiao3, Paul F Worley3, Barbara Noli4, Cristina Cocco4, Gian-Luca Ferri4, Afina W Lemstra2, Charlotte E Teunissen1,2. 1. Neurochemistry Department, Clinical Chemistry, Amsterdam UMC, 1081 HV Amsterdam, The Netherlands. 2. Department of Neurology, Alzheimer Center Amsterdam, Amsterdam UMC, 1081 HV Amsterdam, The Netherlands. 3. Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. 4. NEF-Laboratory, Department of Biomedical Sciences, University of Cagliari, 09042 Monserrato, Italy.
Abstract
Background: Dementia with Lewy bodies (DLB) is a neurodegenerative disease where synaptic loss and reduced synaptic integrity are important neuropathological substrates. Neuronal Pentraxin 2(NPTX2) is a synaptic protein that drives the GABAergic inhibitory circuit. Our aim was to examine if NPTX2 cerebral spinal fluid (CSF) levels in DLB patients were altered and how these levels related to other synaptic protein levels and to cognitive function and decline. Methods: NPTX2, VGF, and α-synuclein levels were determined in CSF of cognitive healthy (n = 27), DLB (n = 48), and AD (n = 20) subjects. Multiple cognitive domains were tested, and data were compared using linear models. Results: Decreased NPTX2 levels were observed in DLB (median = 474) and AD (median = 453) compared to cognitive healthy subjects (median = 773). Strong correlations between NPTX2, VGF, and α-synuclein were observed dependent on diagnosis. Combined, these markers had a high differentiating power between DLB and cognitive healthy subjects (AUC = 0.944). Clinically, NPTX2 levels related to global cognitive function and cognitive decline in the visual spatial domain. Conclusion: NPTX2 CSF levels were reduced in DLB and closely correlated to decreased VGF and α-synuclein CSF levels. CSF NPTX2 levels in DLB related to decreased functioning in the visual spatial domain.
Background: Dementia with Lewy bodies (DLB) is a neurodegenerative disease where synaptic loss and reduced synaptic integrity are important neuropathological substrates. Neuronal Pentraxin 2(NPTX2) is a synaptic protein that drives the GABAergic inhibitory circuit. Our aim was to examine if NPTX2 cerebral spinal fluid (CSF) levels in DLB patients were altered and how these levels related to other synaptic protein levels and to cognitive function and decline. Methods: NPTX2, VGF, and α-synuclein levels were determined in CSF of cognitive healthy (n = 27), DLB (n = 48), and AD (n = 20) subjects. Multiple cognitive domains were tested, and data were compared using linear models. Results: Decreased NPTX2 levels were observed in DLB (median = 474) and AD (median = 453) compared to cognitive healthy subjects (median = 773). Strong correlations between NPTX2, VGF, and α-synuclein were observed dependent on diagnosis. Combined, these markers had a high differentiating power between DLB and cognitive healthy subjects (AUC = 0.944). Clinically, NPTX2 levels related to global cognitive function and cognitive decline in the visual spatial domain. Conclusion: NPTX2 CSF levels were reduced in DLB and closely correlated to decreased VGF and α-synuclein CSF levels. CSF NPTX2 levels in DLB related to decreased functioning in the visual spatial domain.
Authors: Betty M Tijms; Eline A J Willemse; Marissa D Zwan; Sandra D Mulder; Pieter Jelle Visser; Bart N M van Berckel; Wiesje M van der Flier; Philip Scheltens; Charlotte E Teunissen Journal: Clin Chem Date: 2017-12-05 Impact factor: 8.327
Authors: Elizabeta B Mukaetova-Ladinska; Alina Andras; Joan Milne; Zeinab Abdel-All; Iwo Borr; Evelyn Jaros; Robert H Perry; William G Honer; Andrea Cleghorn; Jeanette Doherty; Gary McIntosh; Elaine K Perry; Raj N Kalaria; Ian G McKeith Journal: J Neuropathol Exp Neurol Date: 2013-01 Impact factor: 3.685
Authors: Noam D Beckmann; Wei-Jye Lin; Minghui Wang; Ariella T Cohain; Alexander W Charney; Pei Wang; Weiping Ma; Ying-Chih Wang; Cheng Jiang; Mickael Audrain; Phillip H Comella; Amanda K Fakira; Siddharth P Hariharan; Gillian M Belbin; Kiran Girdhar; Allan I Levey; Nicholas T Seyfried; Eric B Dammer; Duc Duong; James J Lah; Jean-Vianney Haure-Mirande; Ben Shackleton; Tomas Fanutza; Robert Blitzer; Eimear Kenny; Jun Zhu; Vahram Haroutunian; Pavel Katsel; Sam Gandy; Zhidong Tu; Michelle E Ehrlich; Bin Zhang; Stephen R Salton; Eric E Schadt Journal: Nat Commun Date: 2020-08-07 Impact factor: 14.919
Authors: Inger van Steenoven; Nour K Majbour; Nishant N Vaikath; Henk W Berendse; Wiesje M van der Flier; Wilma D J van de Berg; Charlotte E Teunissen; Afina W Lemstra; Omar M A El-Agnaf Journal: Mov Disord Date: 2018-11-15 Impact factor: 10.338
Authors: Sofia Bergström; Linn Öijerstedt; Caroline Graff; Peter Nilsson; Julia Remnestål; Jennie Olofsson; Abbe Ullgren; Harro Seelaar; John C van Swieten; Matthis Synofzik; Raquel Sanchez-Valle; Fermin Moreno; Elizabeth Finger; Mario Masellis; Carmela Tartaglia; Rik Vandenberghe; Robert Laforce; Daniela Galimberti; Barbara Borroni; Chris R Butler; Alexander Gerhard; Simon Ducharme; Jonathan D Rohrer; Anna Månberg Journal: Mol Neurodegener Date: 2021-11-27 Impact factor: 14.195
Authors: Nerea Gómez de San José; Federico Massa; Steffen Halbgebauer; Patrick Oeckl; Petra Steinacker; Markus Otto Journal: J Neural Transm (Vienna) Date: 2021-08-30 Impact factor: 3.575